G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men
- PMID: 31556563
- DOI: 10.5114/pjp.2019.87103
G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men
Abstract
We tested the association between HOXB13 G84E (rs138213197) germline mutation and PC risk in Polish men. DNA from 103 consecutive, newly diagnosed patients hospitalised because of PC and DNA from 103 men: volunteers, healthy at the time of the study. The G84E mutation was genotyped using Sanger sequencing. The HOXB13 G84E germline mutation was detected in 2.9% of PC men (3/103) and not detected in any healthy man. Two mutation carriers originated from two of 25 families fulfilling hereditary prostate cancer criteria (HPC) and one mutation carrier from one family among 78 families without HPC (PC frequency: 8% vs. 1.3%, OR = 6.70, p = 0.13). In two of three mutation carriers, disease was detected above 60 years of age. There was a trend for a lower probability of 5-year survival in patients with G84E than in patients without it (66.7% vs. 94.0%, p = 0.08). The HOXB13 G84E germline mutation is associated with increased prostate cancer risk in Polish men, with hereditary form of the disease, and probably with older age at PC onset (> 60 years of age) and shorter survival. However, it is not associated with PSA level, or PC stage or grade at the time of diagnosis.
Keywords: HOXB13 G84E mutation; clinical characteristics; hereditary predisposition; prostate cancer.
Similar articles
-
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.Ann Oncol. 2015 Apr;26(4):756-761. doi: 10.1093/annonc/mdv004. Epub 2015 Jan 16. Ann Oncol. 2015. PMID: 25595936
-
Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.Oncotarget. 2017 Apr 4;8(14):22772-22782. doi: 10.18632/oncotarget.15196. Oncotarget. 2017. PMID: 28186998 Free PMC article.
-
A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.Eur Urol. 2014 Jan;65(1):169-76. doi: 10.1016/j.eururo.2012.07.027. Epub 2012 Jul 20. Eur Urol. 2014. PMID: 22841674
-
Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24,213 cases and 73, 631 controls.Eur Urol. 2013 Jul;64(1):173-6. doi: 10.1016/j.eururo.2013.03.007. Epub 2013 Mar 14. Eur Urol. 2013. PMID: 23518396 Review. No abstract available.
-
Screening for familial and hereditary prostate cancer.Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5. Int J Cancer. 2016. PMID: 26638190 Review.
Cited by
-
Evaluation of homeobox protein B13 (HOXB13) gene G84E mutation in patients with prostate cancer.World J Urol. 2024 Aug 8;42(1):476. doi: 10.1007/s00345-024-05186-9. World J Urol. 2024. PMID: 39115757
-
Recent Insights on Genetic Testing in Primary Prostate Cancer.Mol Diagn Ther. 2021 Jul;25(4):425-438. doi: 10.1007/s40291-021-00529-3. Epub 2021 Jun 12. Mol Diagn Ther. 2021. PMID: 34118026 Free PMC article. Review.
-
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.Oncogene. 2024 Oct;43(43):3197-3213. doi: 10.1038/s41388-024-03148-4. Epub 2024 Sep 13. Oncogene. 2024. PMID: 39266679 Free PMC article.
-
Hereditary variants of unknown significance in African American women with breast cancer.PLoS One. 2022 Oct 31;17(10):e0273835. doi: 10.1371/journal.pone.0273835. eCollection 2022. PLoS One. 2022. PMID: 36315513 Free PMC article.
-
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.bioRxiv [Preprint]. 2024 May 7:2024.05.07.592966. doi: 10.1101/2024.05.07.592966. bioRxiv. 2024. Update in: Oncogene. 2024 Oct;43(43):3197-3213. doi: 10.1038/s41388-024-03148-4. PMID: 38766099 Free PMC article. Updated. Preprint.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous